Indivumed and University of Rochester Join Forces for Cancer Research

Indivumed has announced a significant collaboration with the University of Rochester Medical Center (URMC) to enhance research in precision oncology. This partnership, formed on December 10, 2025, aims to accelerate the discovery and development of innovative cancer therapeutics tailored to patients with pressing medical needs.

The collaboration leverages Indivumed’s advanced methodologies for collecting standardized tissue and clinical data, which are crucial for patient-centric cancer research and drug development. By combining their resources, Indivumed and URMC intend to facilitate the creation of patient-derived tumor models, which will enable more effective identification and validation of potential cancer treatments.

Advancing Cancer Treatment through Collaboration

A key aspect of this partnership is the emphasis on minimizing ischemia time to under ten minutes. This quick turnaround enhances the integrity and quality of the biosamples collected, which is vital for research accuracy. The joint initiative will initially target advanced stages of solid tumors, including colorectal (CRC), pancreatic (PDAC), lung, and breast cancers. These areas have been identified as having high medical need, with the potential to expand research efforts to additional cancer types in the future.

Hartmut “Hucky” Land, Deputy Director of the Wilmot Cancer Institute, expressed enthusiasm about the collaboration, stating, “We have worked with Indivumed successfully in the past, and our familiarity with their tissue and multi-omics data approach will provide an excellent foundation.” He emphasized the project’s goal to identify new therapeutics and biomarkers, ultimately aiding clinical decision-making and improving cancer care.

Another significant figure in this collaboration, Hartmut Juhl, CEO and founder of Indivumed, noted, “We are thrilled to deepen our collaboration with URMC. This partnership significantly enhances our ability to identify novel cancer therapeutics in a truly patient-centered approach.” He highlighted the importance of developing primary tumor models for testing new compounds against targets identified through Indivumed’s unique AI-powered data analytics.

Building a Global Network for Cancer Research

Through this agreement, URMC joins the Indivumed Global Clinical Network, which includes a diverse array of prominent hospitals and oncology institutes across North America, Europe, and Asia. The collaboration builds on previous successful joint research efforts, including a recent publication focused on classifying distinct types of colon cancer.

The Wilmot Cancer Institute, an NCI-Designated Cancer Center, serves a population exceeding three million people in Western and Central New York. With a team of over 190 oncology physicians and more than 500 oncology nurses, URMC is at the forefront of cancer care and research in the region.

Indivumed, a biotech firm dedicated to precision oncology, aims to redefine cancer treatment by identifying and developing first-in-class therapeutics. With over twenty years of experience and a unique resource for tissue collection, the company is committed to delivering the most effective therapies to cancer patients.

Both organizations are poised to make significant advancements in cancer research and treatment through this collaboration, potentially leading to breakthroughs that could change the landscape of oncology for patients around the world.